

its receptor and allowing the substance to inhibit the binding between PTHrP and its receptor.

17. (New) The method according to claim 16, wherein the substance is an antagonist against a PTHrP receptor.

18. (New) The method according to claim 16, wherein the substance is an anti-PTHrP antibody.

19. (New) The method according to claim 16, wherein the substance is at least one of a fragment of an anti-PTHrP antibody and a modified form of the fragment.

20. (New) The method according to claim 18 or 19, wherein the antibody is a humanized or chimeric antibody.

21. (New) The method according to claim 20, wherein the antibody is humanized #23-57-137-1 antibody.

22. (New) The method according to claim 18 or 19, wherein the antibody is a monoclonal antibody.

*BS
Concl.*

REMARKS

Applicants have amended claims 1-15 and added new claims 16-22 to more particularly point out and distinctly claim the invention. Claims 1-22 are pending. Attached hereto is a marked-up version of the changes made by the current amendment, captioned "Appendix to the Preliminary Amendment." Both the amended and new claims find support in the claims as originally filed and throughout the

specification, and thus no new matter has been added. Examples of support for the new claims are shown in the table below.

NEW CLAIM	SUPPORT
16	page 2, lines 14-23; page 3, lines 20-25
17	page 2, lines 23-25; page 3, lines 20-28; page 4, lines 4-13
18	page 2, lines 23-25; page 3, line 29 to page 4, line 4
19	page 2, lines 23-25; page 12, line 18 to page 13, line 4; page 13, line 28 to page 14, line 4
20	page 2, lines 23-25; page 3, line 29 to page 4, line 4
21	page 2, lines 25-26; page 3, line 29 to page 4, line 4; page 11, line 26 to page 12, line 6
22	page 3, line 29 to page 4, line 4; page 4, line 25 to page 5, line 4

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 9, 2002

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

APPENDIX TO THE PRELIMINARY AMENDMENT

1. (Twice Amended) A method of maintaining or increasing Agent for ameliorating low vasopressin level comprising administering to a patient at least one substance that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof, allowing the substance to inhibit the binding of PTHrP and its receptor, and maintaining or increasing vasopressin level.
2. (Twice Amended) The agent for ~~ameliorating low vasopressin level~~ method according to claim 1, wherein the substance is an antagonist against a PTHrP receptor.
3. (Twice Amended) The agent for ~~ameliorating low vasopressin level~~ method according to claim 1, wherein the substance is an anti-PTHrP antibody.
4. (Twice Amended) The agent for ~~ameliorating low vasopressin level~~ method according to claim 1, wherein the substance is at least one of a fragment of an anti-PTHrP antibody and a modified form of the fragment.
5. (Twice Amended) The agent for ~~ameliorating low vasopressin level~~ method according to claim 3 or 4, wherein the antibody is a humanized or chimeric antibody.
6. (Twice Amended) The agent for ~~ameliorating low vasopressin level~~ method according to claim 5, wherein the antibody is humanized #23-57-137-1 antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

7. (Twice Amended) The ~~agent for ameliorating low vasopressin level~~ method according to claim 3 or 4, wherein the antibody is a monoclonal antibody.
8. (Twice Amended) The ~~agent for ameliorating low vasopressin level~~ method according to any one of claims 1 to 4, wherein the low vasopressin level results from cancer.
9. (Twice Amended) ~~An agent for ameliorating~~ A method of treating at least one symptom caused by a decrease in vasopressin level comprising administering to a patient at least one substance that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof, allowing the substance to inhibit the binding of PTHrP and its receptor, and increasing vasopressin level.
10. (Twice Amended) The ~~agent for ameliorating at least one symptom caused by a decrease in vasopressin level~~ method according to claim 9, wherein the decrease in vasopressin level results from cancer.
11. (Twice Amended) The ~~agent for ameliorating at least one symptom caused by a decrease in vasopressin level~~ method according to claim 9 or 10, wherein the symptom caused by a decrease in vasopressin level is at least one symptom chosen selected from the group consisting of polyuria, dehydration, mouth dryness and hyperosmolarity.
12. (Twice Amended) ~~An agent for ameliorating~~ A method of treating hyperosmolarity comprising administering to a patient at least one substance that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a

receptor thereof, allowing the substance to inhibit the binding of PTHrP and its receptor,
and increasing vasopressin level.

13. (Twice Amended) The ~~agent for ameliorating hyperosmolarity~~ method
according to claim 12, wherein the hyperosmolarity is associated with at least one of
vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

14. (Twice Amended) ~~An agent for ameliorating~~ A method for treating
dehydration comprising administering to a patient at least one substance that inhibits
the binding between ~~parathyroid hormone-related peptide (PTHrP)~~ and a receptor
thereof, allowing the substance to inhibit the binding of PTHrP and its receptor, and
increasing vasopressin level.

15. (Twice Amended) The ~~agent for ameliorating dehydration~~ method
according to claim 14, wherein the dehydration is associated with at least one of
vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com